Gennova Biopharmaceuticals

What Gennova Biopharmaceuticals does

Gennova Biopharmaceuticals Limited, founded in 2006 and headquartered in Pune, India, is a biotechnology company that develops, manufactures, and commercializes biotherapeutics across cardiovascular, neurology, nephrology, and oncology segments. The company operates as a wholly-owned subsidiary of Emcure Pharmaceuticals Limited and employs 501-1,000 people. Its commercial portfolio includes 9 products: biosimilars (Elaxim/tenecteplase, Vintor/erythropoietin, Xgrast/filgrastim, PEGEX/pegfilgrastim, Hamsyl/pegaspargase, Emgrast-M/sargramostim), one novel product (Tenectase — the world's first third-generation thrombolytic approved for acute ischemic stroke), and two mRNA vaccines (GEMCOVAC-19 and GEMCOVAC-OM, India's first mRNA COVID-19 vaccines and the world's first thermostable mRNA vaccines). Gennova manufactures recombinant products across bacterial, yeast, and mammalian expression platforms using proprietary perfusion-based continuous manufacturing technology and AI-guided process control.

The company's underlying technology stack rests on three proprietary pillars: a self-amplifying mRNA (SaRNA) platform with lyophilized thermostability at 2-8°C that eliminates ultra-cold chain requirements; packed-bed perfusion bioreactor technology paired with periodic counter-current chromatography for downstream processing; and neural network-based AI/ML models for predicting and controlling bio-manufacturing performance. Gennova monetizes through B2B institutional channels — hospitals, government healthcare programs, and tenders — in India, pricing products at approximately one-third the innovator cost. Distribution flows primarily through the Emcure Pharmaceuticals network, with international expansion targeted via the under-development USFDA-compliant facility, planned global clinical trials for three products, and emerging-market partners. The company holds five registered patents (US and EU patents on tenecteplase including the first-ever US patent for tenecteplase in stroke, plus patents on filgrastim purification, pegaspargase lyophilization, and GCSF processes) and maintains active collaborations with NIH, US-FDA, CEPI, GHIT, GE Healthcare, Johns Hopkins, LSHTM, and other global institutions on vaccines for Leishmania, malaria, Nipah, and H5N1.

Name

Gennova Biopharmaceuticals

Legal name

Gennova Biopharmaceuticals Limited

Website

https://gennova.bio

Company type

Private

Founded year

2006

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Gennova Biopharmaceuticals is a Pune-based biotech subsidiary of Emcure Pharmaceuticals that develops and commercializes biosimilars, novel biologics, and mRNA vaccines across cardiovascular, neurology, nephrology, and oncology segments in India.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA) (HLAGAGAC)

akta.pro secondary industry

Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)

Keywords

• Biopharmaceutical products
• Biosimilar therapeutics
• MRNA vaccines
• Recombinant proteins
• Biotherapeutic manufacturing

Headquarters

HQ city

Pune

HQ country

India

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Infrastructure, Operations, Marketing or Sales

Revenue model

1. Biosimilar Products: Gennova commercializes biosimilar products including erythropoietin (Vintor), filgrastim (Xgrast), pegylated filgrastim (PEGEX), and pegaspargase (Hamsyl) for oncology, nephrology, and supportive care markets in India.
2. Generic Biologics: Sale of generic biologics including tenecteplase (Elaxim) for acute myocardial infarction and stroke treatment.
3. mRNA Vaccines: Commercialization of mRNA-based vaccines including GEMCOVAC-OM, India's first Omicron-specific mRNA booster vaccine approved for emergency use.
4. Pioneering Novel Products: Tenectase, a pioneering third-generation thrombolytic approved globally for acute ischemic stroke, represents Gennova's novel product innovation.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels4 records

Core offering

Gennova Biopharmaceuticals develops, manufactures, and commercializes biotherapeutics including biosimilars (Elaxim/tenecteplase, Vintor/erythropoietin, Xgrast/filgrastim, PEGEX/pegfilgrastim, Hamsyl/pegaspargase), novel products (Tenectase for acute ischemic stroke), and mRNA vaccines (GEMCOVAC-19 and GEMCOVAC-OM) for cardiovascular, neurology, nephrology, oncology, and infectious disease segments. The company operates proprietary bacterial, yeast, and mammalian expression platforms with perfusion-based continuous manufacturing and AI-guided bio-manufacturing capabilities.

Product overview

Gennova Biopharmaceuticals is a biotechnology company headquartered in Pune, India, that develops, produces, and commercializes biotherapeutics across cardiovascular, neurology, nephrology, and oncology segments. The company operates as a subsidiary of Emcure Pharmaceuticals and offers a diversified portfolio including biosimilars (Elaxim, Vintor, Xgrast, PEGEX, Hamsyl), pioneering novel products (Tenectase - world's first 3rd-gen thrombolytic for stroke), mRNA-based vaccines (GEMCOVAC-19, GEMCOVAC-OM - India's first mRNA vaccines), and pediatric formulations (Hamsyl Junior). The company manufactures recombinant products using bacterial, yeast, and mammalian-based expression platforms with expertise in perfusion-based continuous manufacturing technologies.

Differentiator

Problem solved

Functional benefit

Brands

• Elaxim: Biosimilar tenecteplase for acute myocardial infarction (AMI) - third-generation thrombolytic
• GEMCOVAC
• Hamsyl
• Hamsyl Junior
• PEGEX
• Vintor
• Xgrast

Products and services

• Elaxim Biosimilar tenecteplase (third-generation thrombolytic) for reduction of mortality associated with acute myocardial infarction (AMI); available in 30mg, 40mg, and 52.5mg vial presentations as a single IV bolus.
• Vintor Biosimilar recombinant erythropoietin (EPO) for patients with Chronic Renal Failure suffering from anemia; produced in CHO cells and available in 2000 to 20000 IU formulations.
• Xgrast Biosimilar filgrastim for cancer patients receiving myelosuppressive chemotherapy, bone marrow transplant, acute myeloid leukemia, and severe chronic neutropenia; available in 150µg, 300µg, and 480µg vials and prefilled syringes.
• PEGEX Pegylated filgrastim (PEG-G-CSF), a covalent conjugate of recombinant human G-CSF and 20kDa monomethoxy polyethylene glycol, indicated for febrile neutropenia in non-myeloid malignancies; supplied as pre-filled syringe with automatic needle shielding.
• Hamsyl Generic pegaspargase (PEGylated L-asparaginase) for Acute Lymphoblastic Leukemia, an orphan indication; available as 3750 IU/5ml vial and has benefited over 10,000 patients since launch.
• Tenectase Third-generation thrombolytic tenecteplase approved for acute ischemic stroke (AIS), pioneering innovation included in India's Guidelines for Prevention and Management of Stroke.
• GEMCOVAC-19 India's first mRNA COVID-19 vaccine developed against the spike protein of Wuhan strain and the world's first thermostable mRNA vaccine against COVID-19.
• GEMCOVAC-OM Omicron-specific self-amplifying mRNA booster vaccine for COVID-19 approved under Restricted Use in Emergency Situation in India; world's first thermostable mRNA vaccine, lyophilized and stable at 2-8°C, administered intradermally via needle-free Tropis device by PharmaJet.
• Hamsyl Junior First-of-its-kind paediatric pack size of pegaspargase with 1500 IU pack size and 2mL fill volume, ensuring precise dosing for children with Acute Lymphoblastic Leukaemia while retaining same API strength (750 IU/mL).
• Emgrast-M Biosimilar sargramostim used in oncology supportive care; Gennova is the only Indian manufacturer of this product.

Quantifiable outcome

• Elaxim delivered to >350,000 patients worldwide
• +4 more outcomes

Named customers5 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature5 records

Partnerships

14 partnerships are on record, tiered core and major.

• Houston Methodist Research InstitutecoreStrategic or Co-development PartnerCollaboration with Gennova on mRNA Nipah virus vaccine development, combining Gennova's mRNA platform with the institute's research capabilities.
• US-FDAcoreStrategic or Co-development PartnerCollaborative vaccine program with US-FDA for development and manufacturing of genetically modified live attenuated Leishmania vaccine candidate, a significant testimony to Gennova's capabilities.
• McGill UniversitymajorStrategic or Co-development PartnerPartnership in Leishmania vaccine development program funded by GHIT, Japan.
• Ohio State UniversitymajorStrategic or Co-development PartnerCollaboration on Leishmania vaccine development program.
• Nekken Institute of Tropical MedicinemajorStrategic or Co-development PartnerInternational collaboration for Leishmania vaccine development.
• Johns Hopkins University (JHU)majorStrategic or Co-development PartnerCollaboration on Leishmania vaccine and other vaccine development programs.
• GE HealthcarecoreStrategic or Co-development PartnerCollaboration on Pre-Hospital Thrombolysis (PHT) program implementing emergency cardiac care across India. GE provides portable ECG devices and data transmission infrastructure for remote diagnosis and treatment.
• PATH Malaria Vaccine Initiative (MVI)majorStrategic or Co-development PartnerCollaboration on malaria vaccine development addressing endemic diseases.
• Infectious Disease Research Institute (IDRI)majorStrategic or Co-development PartnerCollaboration on vaccine development for infectious diseases.
• National Institutes of Health (NIH)majorStrategic or Co-development PartnerLong-standing collaboration on vaccine development including Leishmania vaccine and other tropical disease research.
• University of Delhi South Campus (UDSC)majorStrategic or Co-development PartnerAcademic collaboration on vaccine research and development.
• The London School of Hygiene & Tropical Medicine (LSHTM)majorStrategic or Co-development PartnerCollaboration on tropical disease vaccine research.
• The Walter and Eliza Hall Institute (WEHI)majorStrategic or Co-development PartnerInternational collaboration on vaccine development research.
• National Institute of Virology (NIV), PunecoreStrategic or Co-development PartnerNIV partnered with Gennova for H5N1 mRNA vaccine development as part of indigenous vaccine candidate program targeting potential pandemic threats.

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Bharat Biotech: Indian biopharmaceutical company developing vaccines (Covaxin) and biotherapeutics. Directly comparable to Gennova in Indian vaccine innovation, DCGI regulatory navigation, and indigenous platform development for infectious diseases.
• Biological E: Indian biopharmaceutical company focused on vaccines and biologics with WHO prequalification. Comparable to Gennova in Indian pediatric vaccines, biosimilars, and supply to government immunization programs.
• Panacea Biotec: Indian biopharmaceutical company with vaccines and biosimilars portfolio. Comparable to Gennova in pediatric vaccines, oncology supportive care, and institutional/government channel distribution in India.
• BioNTech: German mRNA vaccine pioneer (Comirnaty partnership with Pfizer). Directly comparable to Gennova's mRNA platform development, saRNA technology, and ambition to deploy thermostable mRNA vaccines in emerging markets.
• Moderna: Global mRNA vaccine and therapeutics company with platform targeting infectious diseases, oncology, and rare diseases. Comparable to Gennova in mRNA platform technology, vaccine pipeline (COVID, influenza), and emerging market expansion ambitions.
• CureVac: German mRNA technology company developing prophylactic vaccines and cancer therapeutics. Comparable to Gennova in self-amplifying mRNA platform technology, infectious disease pipeline, and pursuit of thermostable mRNA formulations.
• Biocon: Indian biopharmaceutical company and pioneer in biosimilars (insulin, trastuzumab, bevacizumab) with global commercial presence. Directly comparable to Gennova in Indian biosimilar manufacturing, biologic expression platforms, and emerging market commercialization strategy.
• Serum Institute of India: World's largest vaccine manufacturer by doses, headquartered in Pune, India. Comparable to Gennova in India-based vaccine development and manufacturing scale, mRNA platform investment, and emerging market vaccine distribution.

Broad incumbents

• Zydus Lifesciences (Cadila Healthcare): Large Indian pharmaceutical conglomerate with biosimilars, vaccines (ZyCoV-D DNA vaccine), and branded generics. Comparable to Gennova in Indian biosimilar development, novel vaccine platform innovation, and government channel relationships.
• Dr. Reddy's Laboratories: Major Indian multinational pharmaceutical company with biosimilars, generics, and proprietary products. Comparable to Gennova in Indian biosimilar manufacturing (through Dr. Reddy's Biologics), global regulatory capabilities, and emerging market presence.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/kiran406
• LinkedInlinkedin.com/company/gennova-biopharmaceuticals

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Gennova Biopharmaceuticals